RECRUITING

Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.

Official Title

Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease

Quick Facts

Study Start:2024-03-05
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06772220

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 90 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria.
  2. 2. Currently treated with levodopa at a minimum dose of 300 mg/day
  3. 3. Montreal Cognitive Assessment (MOCA) ≥15
  4. 4. Demonstrated capacity to provide informed consent.
  5. 5. 40-90 years of age
  6. 6. Estimated glomerular filtration rate ≥60
  7. 7. Absence of uncontrolled hypertension in medical history
  8. 8. Absence of insulin use
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Madeline Armendariz Sullivan
CONTACT
503-501-8478
PDResearch@ohsu.edu

Principal Investigator

Joseph Quinn, MD
PRINCIPAL_INVESTIGATOR
Oregon Health & Science University (OHSU)

Study Locations (Sites)

Oregon Health & Science University (OHSU)
Portland, Oregon, 97239
United States

Collaborators and Investigators

Sponsor: Oregon Health and Science University

  • Joseph Quinn, MD, PRINCIPAL_INVESTIGATOR, Oregon Health & Science University (OHSU)

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-03-05
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2024-03-05
Study Completion Date2025-12-31

Terms related to this study

Keywords Provided by Researchers

  • Parkinson's disease
  • Parkinson disease
  • homocysteine

Additional Relevant MeSH Terms

  • Parkinson&Amp;#39;s Disease